CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES

Abstract: Particles exhibiting reverse transcriptase activity and associated with mammalian C-type retrovirus structural proteins are disclosed. DNA and complementary DNA sequences of novel retrovirus-like particles are also provided, as well as methods for their use.

Description: Chi nese Hamster Ovary Cel l retrovi rus- l i ke C particl es Background of the Invention This invention relates to recombinant cell culture lines and methods, particularly the identification and use therein of nucleic acid sequences encoding retrovirus-like particles. Retrovirus-like particles are observed in all Chinese hamster ovary (CHO) cells, when thin-sections of cells are viewed by transmission electron microscopy. Two types of particles are consistently observed: Intracytoplasmic A-type particles frequently associated with centrioles, and budding C-type particles {Donahue, P. R. et a/., J. Virol. 62: 722-731 [ 1 988]; Lieber, M.M. Science 1 82:56-58 [1 973]; ubiniecki, Develp.Biol. Standards 70: 1 87-1 91 [1989]; Lubiniecki et al. , Develp.Biol.Sta 60: 141 -146 [1985]; Manley, K. F. J. Gen. Virol. 39:505-517 [1 978]; Tihoπ, C, Nat.New Biol. 244:227-231 [1 973]}. Infection or transmission to other cells has never been detected {ibid., and Hojman, F.R., Develop. Biol. 70: 1 95-202 [ 1 990]}. Despite their apparently non-infectious nature, the origin of the observed retrovirus-like particles is of interest since recombinant CHO cells are used as substrates for the production of biopharmaceuticals intended for human use {Collen, D., J.Pharm.Exp. 231 : 146-1 52 [ 1 984]; Patzer, E.J., BioTechnology 4:630-636 [ 1 986]; Egrie, J.C., Prog. Gin. Biol. 1 91 :339-350 [1 985]}. To the extent that reverse transcriptase activity, indicative of potential biological activity, is shown to be associated with retrovirus-like particles in recombinant cell lines, concern is heightened regarding potential transmission of virus to recipients of biopharmaceutical products. Antisense technology has previously been used to inhibit expression of specific gene products in mammalian cell lines (Kasid et al. , Science 243: 1354-1 356 [1 989]; Khoka et al.. Science 243:947-950 [1 989]; Izant et al., Science 229:345-352 [1985]) including some retroviruses; (von Ruden et al. , J. Virol. 63:677-682 [1 989]; Chang et al. , J . Virol. 61 :921 -924 [1 987]), but not all attempts have been successful (Kerr et al. , Eur. J. Biochem. 175:65-73 [1988]). The secondary structure of the target RNA may influence susceptibility to antisense inhibition. Antisense inhibition is currently believed to require an excess of antisense RNA relative to coding mRNA in order to be effective. Ribozymes are small RNA molecules that can cleave substrate RNAs in a sequence specific manner. For example, "hammerhead" ribozymes are described by Haseloff et al., Nature 334:585-591 [1 988] which cleave mRNAs at specific sites in vitro. With these hammerhead ribozymes, target sequences need only contain a GUA or GUC sequence at which cleavage occurs. Specificity of cleavage is determined by flanking sequences which hybridize to the ribozyme sequence. Thus, ribozymes can be engineered to cleave at any 1 8 bp RNA sequence flanking a GUA or GUC triplet, thus generating very precise specificity. Published literature also describes RNA enzymes with highly specific endoribonuclease activities, such as those disclosed by Koizumi et al. , FEBS Lett. 239:285-288 [1 988] . Ribozymes have also been used with in vivo applications; for example, in unpublished data, it has been demonstrated that insertion of a ribozyme sequence into a tRNA gene improves stability in vivo, and that tRNA/ribozyme constructs specific for the tat gene of HIV-I may inhibit transactivation of the HIV-I LTR promoter by the HIV-I tat product. Because of the low numbers of retrovirus-like particles heretofore shown to be present in CHO cells, recognition and characterization has been difficult. It is therefore an object of this invention to identify and characterize novel extracellular C-type retrovirus-like particles in culture fluid from a recombinant CHO cell line. Methods for the detection of these particles are also objects of this invention. A further object of this invention is to provide methods for increased or decreased expression of these retrovirus-like particles in cultured cells. Methods for the isolation of cell lines with reduced or undetectable levels of C-type particles, or reverse transcriptase activity associated with those particles, are provided. Such cell lines provide an ideal parental line for subsequent genetic modification and use as a substrate for production of biopharmaceuticals, because regulatory requirements for viral clearance and inactivation studies during manufacturing processes would be minimized and concerns regarding transmissibility of retrovirus particles would be obviated. Summary of the Invention The objects of this invention are accomplished through novel nucleic acid sequences which encode extracellular retrovirus-like particles and provirus sequences. Further objects have been accomplished by a method comprising providing cells transformed with such nucleic acid, or cells containing such nucleic acid operably linked to exogenous control sequences, culturing the host cell to allow the retrovirus-like particles to accumulate in the culture, and recovering them from the culture. Surprisingly, a full-length clone encoding these retrovirus-like particles has been identified and recovered. These sequences have been found to be present as conserved, repetitive, provirus sequences in genomic DNA of CHO cell lines and in Chinese hamster liver DNA. Polynucleotide probes can be made for determining the level of transcription of said DNA in cells and receptors produced capable of specifically recognizing determinant sites of peptide products of said DNA sequences. The probes and receptors may be labeled with a wide variety of labels for a variety of applications. Yet another object is to provide molecules with novel characteristics for use as diagnostic reagents for the in vitro assay of the retroviruses. The sequences provided by this invention have homology to the conserved endonuclease domain of a murine leukemia virus, but the present sequences contain multiple interruptions of the endonuclease-encoding reading frame. Because the claimed sequences do not effectively code for an endonuclease, which is required for virus integration and replication, the retrovirus-like particles of this invention are presently believed to be non-infectious. Methods for increasing or decreasing expression of these particles in cell culture are provided, utilizing complementary (antisense) nucleic acid sequences, ribozymes, RNA nucleases, DNA control sequences and exogenous translation modulatory elements. Cells having increased or decreased expression of these particles are provided, as well as methods for the detection of expression levels. The compositions and methods of this invention find application to the detection of contaminants in recombinant cell culture production, for example through the use of PCR, immunoassay or other means of identifying these retrovirus-like particles in a product sample. Brief Description of the Drawings Figure 1 . Purification of particles from CHO 3-3000-44 cells using a double sucrose gradient protocol. 4000-fold concentrated culture fluid from CHO 3-3000-44 cells was adjusted to 50% sucrose by addition of powdered sucrose and overlayed with successive layers of 40%, 30% and 20% sucrose. After centrifuging to equilibrium RT containing fractions from the main peak, shown in panel A, were pooled, dialyzed, and layered on top of a preformed 10-60% sucrose gradient and again centrifuged to equilibrium. RT activity in the second gradient is shown in panel B. Figure 2. Electron micrographs of double-gradient purified particles from CHO 3-3000-44 cells. RT containing fractions from the second gradient of a double-gradient purification were pooled, concentrated, and dialyzed. After spotting onto EM grids, particles were visualized by negative staining using uranyl acetate. Shown are three examples of the particles observed. The size and morphology are consistent with previous descriptions of retrovirus particles visualized by this technique. Figure 3. Retrovirus-related proteins and nucleic acids in gradient purified particles. Pools of 4 fractions each from the second gradient of a double-gradient particle purification (shown in Fig. 1 B) were evaluated for the presence of C-type structural proteins and retrovirus nucleic acid sequences. (A) Western blot analysis using goat anti-FeLV p27 serum as probe for C-type retrovirus structural proteins. The p31 band represents the major core protein and the p64 band represents unprocessed gag precursor. (B) Nucleic acids were extracted from samples of each pool, applied to membranes and hybridized to the indicated probes. Cytoplasmic RNAs from CHO cells and MRC5 cells (human diploid fibroblasts) were used as controls. Figure 4. Homology of pCHOC.MLI O cDNA with Moloney MLV genome. The nucleotide sequence of the Moloney MLV genome {Shinnick, T., Nature 293:543-548 [1981 ]} is plotted on the horizontal axis, and the pCHOC.MLI 0 nucleotide sequence is plotted on the vertical axis. Each dot represent 75 % identity over a stretch of 1 6 nucleotides. Regions of significant homology appear as diagonal lines. Organization of the Moloney MLV RNA genome is shown for orientation. Figure 5. Initiation and stop codons of the pCHOC.MLIO sequence. Methionine codons (M) and stop codons (0) in the three reading frames of the strand collinear with the Moloney MLV genome are shown. Multiple interruptions of coding sequences in all three reading frames are present. No significant open reading frames were observed on the opposite strand. Figure 6. Blot analysis of C-type provirus sequences in genomic DNA of CHO cells and Chinese Hamster liver. Hindlll digested DNAs (2 μg per lane) isolated from parental and recombinant CHO cell lines and from Chinese hamster liver were fractionated on agarose gels, blotted onto membranes and hybridized with retrovirus probes. CHO-K1 is the ancestral cell line from which all others shown are derived. CHO-dhfr " is the parent line, CHO-DUXB1 . , from which the recombinant line, CHO 3-3000-44 (designated here as CHO-44) was derived following transfection with an expression vector. Copy number controls are restriction enzyme cut plasmid loaded onto the gel so that the amount of insert is equivalent to the indicated number of copies per Chinese hamster haploid genome. Labeled Hindlll fragments of lambda DNA were used as molecular weight markers (MW). Sizes in kilobase pairs of molecular weight markers are indicated to the right of each panel. Deduced sizes of major genomic Hindlll fragments hybridizing with each probe are shown to the left of each panel. (A) C-type related sequences were detected by hybridization with the pCHOC.MLI O partial cDNA clone representing purified particle RNA (see text). Copy number controls are EcoR1 digested pCHOC.MLI O plasmid. The 0.6 kb genomic Hindlll fragment was predicted from the sequence of the pCHOC.MLI O clone used as probe. (B) CHO IAP family II related sequences were detected by hybridization with the pCHIAP.YL9 cellular cDNA clone {Anderson, K. P. et al., J. Virol. 64:2021-2032 [1990]}. Related sequences were observed in purified extracellular particles of CHO cells (see Figure 3). Copy number controls are Hindlll digested pCHIAP.YL9 plasmid. Detailed Description C-type retrovirus-like particles are budding particles with retrovirus-like morphology and immunological characteristics, described generally in the literature cited above. Intracytoplasmic A-type particles frequently associated with centrioles are specifically excluded from this definition. C-type retrovirus nucleic acid sequences are defined herein as sequences encoding such particles, allowing for multiple interruptions of potential coding sequences. Homology with respect to a C-type retrovirus sequence is defined herein as the percentage of residues in the candidate sequence that are identical with the residues in the sequences identified below as Seq. ID No. 1 and Seq. ID No 2., after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Homology with respect to a C-type retrovirus particle is defined similarly with respect to the particles encoded by such sequences. Where the candidate sequence is a fragment of a the particles encoded by Seq. ID No 1 , it preferably but not necessarily has at least - 75% homology to the C-type retrovirus particle as defined herein. Included within the scope of the C-type retrovirus particle as that term is used herein are particles having the amino acid sequences encoded by Seq. ID No. 1 , glycosylated or unglycosylated derivatives of the particle, homologous amino acid sequence variants of the sequences encoded by Seq. ID No. 1 , and homologous in ' fλo-generated variants and derivatives of the amino acid sequences encoded by Seq. ID No. 1 , which are capable of exhibiting a biological activity in common with the particles encoded by Seq. ID No. 1 . C-type particle biological activity is defined as immunological cross-reactivity with at least one epitope of a C-type retrovirus-like particle encoded by Seq. ID No. 1 . Immunoiogically cross-reactive as used herein means that the candidate polypeptide is capable of competitively inhibiting the qualitative biological activity of the C-type retrovirus- like particle having this activity with polyclonai antisera raised against the known active analogue. Such antisera are prepared in conventional fashion by injecting goats or rabbits, for example, subcutaneously with the known active analogue in complete Freund's adjuvant, followed by booster intraperitoneal or subcutaneous injection in incomplete Freunds. An "exogenous" element is defined herein to mean foreign to the cell, or homologous to the cell but in a position within the host cell in which the element is ordinarily not found. Novel nucleic acid compositions are provided herewith. This invention encompasses the following DNA sequence (Seq. ID No. 1 ) which encodes an RNA transcript of a C-type retrovirus-like particle endogenous in CHO cells. Sequence ID No. 1 : (5' to 3'): GAATTCAATG TCCTTGTGGG GAAGAACGAT ATTCTAAAAC AGGTAACTGA 50 GCAATGTGAT GCGTGCGCCC GAGTCAACGC ATCCAGACTG AAGCTTCCTC 100 CCGGGAACCG GTCAGAGGCT ACCGGCCCGG AACACATTGG GAGATAGATT 150 TCACTGAGAT TAAACCAGGA AAATATGGAT ACAAGTATCT ATTAATTTTT 200 GTAGACACCT TTTCAGGATG GGTTGAAGCC TTCCCTACTA AACATGAAAC 250 AGCCAGATCG TTACTAAGAA ATTGCTTGAA GAAATCTTTC CCCGTTATCG 300 GATGCCTCAG GTATTGGGAA CAGACAATGG GCCCGCCTTC GTCTCCAGGT 350 AAGTCAGTCA GTGGCCACCT TATTGGGGAT TGATTGGAAA TTACATTGTG 400 CTTATAGACC CCAAAGTTCA GGACAGGTAG AAAGGATGAA TAGAACAATC 450 AAGGAGACTT TAACAAAATT GTCGCTTGCA ACTGGCACTA GAGAGCTGGG 500 TCCTCCTACT CCCCCTAGCA CTCTACCGCG CTCGTAATAC CCCTGGACCA 550 CATGGGCTCA CACCCTTTGA GATCCTGTAT GGAGTACCTA GCTCCTATCA 600 TTAACTTTCT TGATCAAGAT GTCTCAGTTT TGCTAACTCC CCTTCTCTCC 650 AAGCTCATTT ACAGGCCCTC CAACTAGTAC AACGGGAGGT CTGGAAACCC 700 CTTGCTCAAG CTTATAAAGA CCAGAGGGAC CATCCCACCA TCCCCCATTC 750 CTACCAGATC GGGGACACTG TTTGGGTCCG GCGTCACCAG GCCAAGAACC 800 TTGAACCCCG CTGGAAGGGA CCCTACATCG TTTTGCTTAC CACTCCCACC 850 GCACTCAAGG TAGACGGCAT TGCAGCTTGG ATACATGCTT CACATGTAAA 900 GCCAGCCCAA CCCACCGATT CAGCCACTGC ATCAGAATGG AGCCACACC 949 This invention further encompasses fragments of such DNA and RNA sequences which retain hybridization specificity. Novel nucleic acid compositions which are complementary (antisense) to the sequences just described are encompassed herewith. The following DNA sequence (Seq. ID No. 2) is complementary to Seq. ID No. 1 , and encodes an RNA transcript complementary to the RNA transcript of the C-type retrovirus-like particle endogenous in CHO cells described above. Sequence ID No.2: (5' to 3'): GGTGTGGCTC CATTCTGATG CAGTGGCTGA ATCGGTGGGT TGGGCTGGCT 50 TTACATGTGA AGCATGTATC CAAGCTGCAA TGCCGTCTAC CTTGAGTGCG 100 GTGGGAGTGG TAAGCAAAAC GATGTAGGGT CCCTTCCAGC GGGGTTCAAG 150 GTTCTTGGCC TGGTGACGCC GGACCCAAAC AGTGTCCCCG ATCTGGTAGG 200 AATGGGGGAT GGTGGGATGG TCCCTCTGGT CTTTATAAGC TTGAGCAAGG 250 GGTTTCCAGA CCTCCCGTTG TACTAGTTGG AGGGCCTGTA AATGAGCTTG 300 GAGAGAAGGG GAGTTAGCAA AACTGAGACA TCTTGATCAA GAAAGTTAAT 350 GATAGGAGCT AGGTACTCCA TACAGGATCT CAAAGGGTGT GAGCCCATGT 400 GGTCCAGGGG TATTACGAGC GCGGTAGAGT GCTAGGGGGA GTAGGAGGAC 450 CCAGCTCTCT AGTGCCAGTT GCAAGCGACA ATTTTGTTAA AGTCTCCTTG 500 ATTGTTCTAT TCATCCTTTC TACCTGTCCT GAACTTTGGG GTCTATAAGC 550 ACAATGTAAT TTCCAATCAA TCCCCAATAA GGTGGCCACT GACTGACTTA 600 CCTGGAGACG AAGGCGGGCC CATTGTCTGT TCCCAATACC TGAGGCATCC 650 GATAACGGGG AAAGATTTCT TCAAGCAATT TCTTAGTAAC GATCTGGCTG 700 TTTCATGTTT AGTAGGGAAG GCTTCAACCC ATCCTGAAAA GGTGTCTACA 750 AAAATTAATA GATACTTGTA TCCATATTTT CCTGGTTTAA TCTCAGTGAA 800 ATCTATCTCC CAATGTGTTC CGGGCCGGTA GCCTCTGACC GGTTCCCGGG 850 AGGAAGCTTC AGTCTGGATG CGTTGACTCG GGCGCACGCA TCACATTGCT 900 CAGTTACCTG TTTTAGAATA TCGTTCTTCC CCACAAGGAC ATTGAATTC 949 Within the scope of this invention is this complementary DNA, as well as complementary RNA transcripts, and fragments of such complementary DNA and RNA sequences which retain hybridization specificity. This invention also contemplates amino acid sequence variants of the C-type particles encoded by Seq. ID No. 1. Amino acid sequence variants of the particle are prepared with various objectives in mind, including increasing the binding affinity of the particle for its ligand, modulating its infectivity/transmissibility, and facilitating its stability, purification and preparation. Amino acid sequence variants of the retrovirus-like particles of this invention fall into one or more of three classes: Insertional, substitutional, or deletional variants. These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the particle, by which DNA encoding the variant is obtained, and thereafter expressing the DNA in recombinant cell culture. However, fragments having up to about 100-150 amino acid residues are prepared conveniently by in vitro synthesis. The amino acid sequence variants of the C-type retrovirus-like particle of this invention are predetermined variants not found in nature or naturally occurring alleles. The variants typically exhibit the same qualitative biological--for example, receptor binding-activity as the naturally occurring analogue. However, the variants and derivatives that are not capable of binding to a receptor are useful nonetheless (a) as a reagent in diagnostic assays for the C- type retrovirus-like particle of this invention or antibodies thereto, (b) when insolubilized in accord with known methods, as agents for purifying anti-retroviral antibodies from antisera or hybridoma culture supernatants, and (c) as immunogens for raising antibodies to the C-type retrovirus of this invention or as immunoassay kit components (labelled, as a competitive reagent for the native particle or unlabelled as a standard for the C-type particle assay) so long as at least one C-type retrovirus-like epitope remains active. While the site for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random or saturation mutagenesis (where all 20 possible residues are inserted) is conducted at the target codon and the expressed particle variant is screened for the optimal combination of desired activities. Such screening is within the ordinary skill in the art. Amino acid insertions usually will be on the order of about from 1 to 10 amino acid residues; substitutions are typically introduced for single residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. It will be amply apparent from the following discussion that substitutions, deletions, insertions or any combination thereof are introduced or combined to arrive at a final construct. Insertional amino acid sequence variants are those in which one or more amino acid residues extraneous to the C-type retrovirus-like particle are introduced into a predetermined site in the target particle and which displace the preexisting residues. Commonly, insertional variants are fusions of heterologous proteins or polypeptides to the amino or carboxyl terminus of the particle. Such variants are referred to as fusions of the retrovirus-like sequence and a polypeptide containing a sequence which is other than that which is normally found in the particle at the inserted position. Several groups of fusions are contemplated herein. The novel polypeptides of this invention are useful in diagnostics or in purification of the C-type particle by immunoaffinity techniques known per se. Desirable fusions of the C-type particle of this invention which may or may not also be retrovirally active, include fusions of the mature particle sequence with a signal sequence ' heterologous to the binding partner. Signal sequence fusions are employed in order to more expeditiously direct the secretion of the particle. The heterologous signal replaces the native particle signal, and when the resulting fusion is recognized, i.e. processed and cleaved by the host cell, the retrovirus-like particle is secreted. Signals are selected based on the intended host cell, and may include bacterial yeast, mammalian and viral sequences. The native LHR signal or the herpes gD glycoprotein signal is suitable for use in mammalian expression systems. Substitutional variants are those in which at least one residue in the sequences encoded by the Seq. ID No. 1 sequence has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the common practice when it is desired to finely modulate the characteristics of the particle. Novel amino acid sequences, as well as isosteric analogs (amino acid or otherwise), as included within the scope of this invention. Substantial changes in function orimmunological identity are made by selecting residue substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. Some deletions, insertions, and substitutions will not produce radical changes in the characteristics of the C-type particle. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, however one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. For example, a variant typically is made by site specific mutagenesis of the particle-encoding nucleic acid, expression of the variant nucleic acid in recombinant cell culture and, optionally, purification from the cell culture for example by immunoaffinity adsorption on a polyclonal anti-C-type retrovirus column {in order to adsorb the variant by at least one remaining immune epitope). The activity of the cell lysate or purified particle variant is then screened in a suitable screening assay for the desired characteristic. For example, a change in the character of the particle such as retroviral activity, is measured by standard assays. As more becomes known about the functions in vivo of the particles of this invention other assays will become useful in such screening. Modifications of such protein properties as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers are assayed by methods well known to the artisan. Excluded from the scope of deletional variants are the digestion fragments heretofore obtained in the course of elucidating amino acid sequences of C-type particles, and protein fragments having less than - 75% sequence homology to any particle encoded by Seq. ID No 1 or 2. Covaleπt modifications of the retrovirus-like particle are included within the scope hereof. Such modifications are introduced by reacting targeted amino acid residues of the recovered protein with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues, or by harnessing mechanisms of post-translational modification that function in selected recombinant host cells. The resulting covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays or for the preparation of anti-particle antibodies for immunoaffinity purification of the recombinant retrovirus-like particle. Such modifications are within the ordinary skill in the art and are performed without undue experimentation. Nucleic acid encoding the C-type retrovirus-like particles of this invention is synthesized by in vitro methods or is obtained readily from cDNA libraries. The means for synthetic creation of the DNA encoding the particle, either by hand or with an automated apparatus, are generally known to one of ordinary skill in the art, particularly in light of the teachings contained herein. As examples of the current state of the art relating to polynucleotide synthesis, one is directed to Maniatis et al., Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory (1984), and Horvath et al., An Automated DNA Synthesizer Employing Deoxynucleoside 3'-Phosphoramidites, Methods in Enzymology 154: 313-326, 1987. Alternatively, to obtain DNA encoding the particle from sources other than hamster, since the entire DNA sequence for the preferred embodiment of the C-type retrovirus-like particle (Seq. ID No. 1 ) is given, one needs only to conduct hybridization screening with labelled DNA encoding the particle or fragments thereof (usually, greater than about 20, and ordinarily about 50bp) in order to detect clones which contain homologous sequences in the cDN A libraries of the particular animal, followed by analyzing the clones by restriction enzyme analysis and nucleic acid sequencing to identify full-length clones. If full length clones are not present in the library, then appropriate fragments are recovered from the various clones and ligated at restriction sites common to the fragments to assemble a full-length clone. DNA encoding retrovirus-like particles from other animal species is obtained by probing libraries from such species with the hamster sequences, or by synthesizing the genes in vitro. DNA for other retrovirus-like particles having known sequence may be obtained with the use of analogous routine hybridization procedures. Provided herein are nucleic acid sequences that hybridize under stringent conditions to a fragment of the DNA sequence of Seq. ID No. 1 , which fragment is greater than about 1 0 bp, preferably 20-50 bp, and even greater than 100 bp. Also included within the scope hereof are nucleic acid sequences that hybridize under stringent conditions to a fragment of Seq. ID No. 1 or Seq. ID No. 2, and which retain such hybridization specificity to these sequences. Included also within the scope hereof are nucleic acid probes which are capable of hybridizing under stringent conditions to the DNA of Seq. ID No. 1 or 2, or to the genomic gene for the C-type retrovirus-like particle (including introns and 5' or 3' flanking regions extending to the adjacent genes or about 5,000 bp, whichever is greater). Identification of the genomic DNA for the C-type particle is a straight-forward matter of probing a particular genomic library with the cDNA or its fragments which have been labelled with a detectable group, e.g. radiophosphorus, and recovering clone(s) containing the gene. The complete gene is pieced together by "walking" if necessary. Typically, such probes do not encode sequences with less than 75% homology to the particles of this invention, and they range from about from 10 to 100 bp in length. Homologies and sizes with respect to other retrovirus-like particles may be determined without undue experimentation. Hybrid DNA technology may be employed for obtaining expression. The DNA sequence may be restriction mapped and appropriate sites for cleavage defined. In this way, the sequence may be excised and introduced into a vector having the appropriate control, transcription modulatory regions and regulatory signals. After obtaining expression of the DNA sequence, particles may be purified and antibodies can be made to them. In general, prokaryotes are used for cloning of DNA sequences in constructing the vectors useful in the invention. For example, E. co/i K .2 strain 294 (ATCC No. 31446) is particularly useful. Other microbial strains which may be used include E. coli B and E. co/i X1776 (ATCC No. 31537). These examples are illustrative rather than limiting. Alternatively, in vitro methods of cloning, e.g. polymerase chain reaction, are suitable. The polypeptides of this invention are expressed directly in recombinant cell culture as an N-terminal methionyl analogue, or as a fusion with a heterologous polypeptide, preferably a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the particle/portion. For example, in constructing a prokaryotic secretory expression vector for the particle, the native C-type particle signal is employed with hosts that recognize that signal. When the secretory leader is "recognized" by the host, the host signal peptidase is capable of cleaving a fusion of the leader polypeptide fused at its C-terminus to the desired mature retrovirus-like particle. For host prokaryotes that do not process the retrovirus-like particle signal, the signal is substituted by a prokaryotic signal selected for example from the group of the alkaline phosphatase, penicillinase, Ipp or heat stable enterotoxin II leaders. For yeast secretion the native signal may be substituted by the yeast invertase, alpha factor or acid phosphatase leaders. In mammalian cell expression the native signal is satisfactory, although other mammalian secretory protein signals are suitable, as are viral secretory leaders, for example the herpes simplex gD signal. The novel particles of this invention may be expressed in any host cell, but preferably are synthesized in mammalian hosts. However, host cells from prokaryotes, fungi, yeast, " insects and the like are also are used for expression. Exemplary prokaryotes are the strains suitable for cloning as well as E. coli W31 10 (F'Λ '* prototrophic, ATTC No. 27325), other enterobacteriaceae such as Serratia marcescans, bacilli and various pseudomonads. Preferably the host cell should secrete minimal amounts of proteolytic enzymes. Expression hosts typically are transformed with DNA encoding the hybrid which has been ligated into an expression vector. Such vectors ordinarily carry a replication site (although this is not necessary where chromosomal integration will occur). Expression vectors also include marker sequences which are capable of providing phenotypic selection in transformed cells, as will be discussed further below. For example, E. coli is typically transformed using pBR322, a plasmid derived from an E. coli species (Bolivar, et al.., Gene 2: 95 [1 977]). pBR322 contains genes for ampiciliin and tetracycline resistance and thus provides easy means for identifying transformed cells, whether for purposes of cloning or expression. Expression vectors also optimally will contain sequences which are useful for the control of transcription and translation, e.g., promoters and Shine-Dalgarno sequences (for prokaryotes) or promoters and enhancers (for mammalian cells). The promoters may be, but need not be, inducible. While it is conceivable that expression vectors need not contain any expression control, replicative sequences or selection genes, their absence may hamper the identification of transformants and the achievement of high level particle expression. Promoters suitable for use with prokaryotic hosts illustratively include the /Hactamase and lactose promoter systems (Chang et al., "Nature", 275: 61 5 [1 978]; and Goeddel et al. , "Nature" 281 : 544 [1 979]), alkaline phosphatase, the tryptophan (trp) promoter system (Goeddel "Nucleic Acids Res. " 8: 4057 [1980] and EPO Appln. Publ. No. 36,776) and hybrid promoters such as the tac promoter (H. de Boer et al., "Proc. Natl. Acad. Sci. USA" 80: 21 - 25 [1983]). However, other functional bacterial promoters are suitable. Their nucleotide sequences are generally known, thereby enabling a skilled worker operably to ligate them to DNA encoding the LHR (Siebenlist et al., "Cell" 20: 269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the C-type retrovirus- like particle. In addition to prokaryotes, eukaryotic microbes such as yeast or filamentous fungi are satisfactory. Saccharomvces cerevisiae is the most commonly used eukaryotic microorganism, although a number of other strains are commonly available. The plasmid YRp7 is a satisfactory expression vector in yeast (Stinchcomb, et al. ,, Nature 282: 39 [1 979]; Kingsman et a/., Gene 7: 141 [1 979]; Tschemper et a/., Gene 10: 1 57 [1 980]). This plasmid already contains the trpl gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC no. 44076 or PEP4-1 (Jones, Genetics .85: 12 [1977]). The presence of the trpl lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by " growth in the absence of tryptophan. Suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase (Hitzeman et a/., "J. Biol. Chem." 255: 2073 [1980]) or other glycolytic enzymes (Hess et al., "J. Adv. Enzyme Reg." 2* 149 [1968]; and Holland, "Biochemistry" J2- 4900 [1 978]), such as enolase, glyceraIdehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6- phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., European Patent Publication No. 73,657A. Expression control sequences are known for eucaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence which may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are inserted into mammalian expression vectors. Suitable promoters for controlling transcription from vectors in mammalian host cells are readily obtained from various sources, for example, the genomes of viruses such as polyoma virus, SV40, adenovirus, MMV (steroid inducible), retroviruses (e.g. the LTR of HIV), hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. the beta actin promoter. The early and late promoters of SV40 are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication. Fiers et a/., Nature, 273: 113 (1978). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment. Greenaway, P.J. et a/., Gene 1.8: 355-360 (1982). Transcription of a DNA encoding the retrovirus-like particles of this invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis- acting elements of DNA, usually about from 10-300bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having been found 5' (Laimins, L et a/., PNAS 28: 993 [1981 ]) and 3' (Lusky, M.L, et al., Mol. Ceil Bio. 3: 1 108 [1 983]) to the transcription unit, within an intron (Banerji, J.L. et al., Cell 33: 729 [1983]) as well as within the coding sequence itself (Osborne, T.F., et al., Mol. Cell Bio. 4: " 1293 [1 984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, σ-fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding the particle. The 3' untranslated regions also include transcription termination sites. Expression vectors may contain a selection gene, also termed a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase (TK) or neomycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell is able to survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are CHO DHFR " cells and mouse LTI cells. These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non supplemented media. The second category of selective regimes is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet. 1: 327 (1 982)), mycophenolic acid (Mulligan eta/. , Science 209: 1422 (1980)) or hygromycin (Sugden et a/., Mol. Cell. Biol. 5_: 410-413 (1 985)). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G41 8 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Suitable eukaryotic host cells for expressing the C-type retrovirus-like particle include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1 651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham, F.L. et a/., J. Gen Virol. 36: 59 [1 977]); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary-cells-DHFR (CHO, Urlaub and Chasin, PNAS (USA) 7,7: 4216, [1980]); mouse sertoli cells (TM4, Mather, J.P., Biol. Reprod. 23: 243-251 [1 980]); monkey kidney cells (CV1 ATCC CCL 70); african green monkey kidney cells (VERO-76, ATCC CRL-1 587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51 ); and, TRI cells (Mather, J.P. et al., Annals N.Y. Acad. Sci. 383: 44-68 [1 982]). Construction of suitable vectors containing the desired coding and control sequences employ standard ligation techniques. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to form the plasmids required. For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform £ co// ' K12 strain 294 {ATCC 31446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction and/or sequenced by the method of Messing et a/. , Nucleic Acids Res. 9: 309 (1 981 ) or by the method of Maxam et a/. , Methods in Enzymology 6E5: 499 (1 980). Host cells are transformed with the expression vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants or amplifying the genes encoding the desired sequences. The host cells used to practice this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium {[MEM], Sigma), RPM1-1 640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DME], Sigma) may be suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace (Meth. Enz„ 58: 44 [1 979]), Barnes and Sato (Anal. Biochem., 102:255 [1 980]), U.S. Patent 4,767,704, U.S. Patent 4,657,866, WO 90/03430, WO 87/001 95, U.S. Patent Re. 30,985, U.S. Patent 4,927,762, or U.S. Patent 4,560,655 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrϊn, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium and phosphate), buffers (such as HEPES), nucieosides (such as adenosine and thymidine), antibiotics (such as Gentamycin), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells which are within a host animal. "Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Unless indicated otherwise, the method used herein for transformation of the host cells is the method of Graham, F. and van der Eb, A., Virology 5_2: 456-457 (1 973). However, other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used. If prokaryotic cells or cells which contain substantial cell wall constructions are used, the preferred method of transfection is calcium treatment using calcium chloride as described by Cohen, F.N. et a/.., Proc. Natl. Acad. Sci. (USA), 69: 21 10 (1 972). "Transfection" refers to the introduction of DNA into a host cell whether or not any coding sequences are ultimately expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO. and electroporation. Transformation of the host cell is the indicia of successful transfection. "PCR" (polymerase chain reaction) refers to a technique whereby a piece of DNA is amplified. Oligonucleotide primers which correspond to the 3' and 5' ends (sense or antisense strand-check) of the segment of the DNA to be amplified are hybridized under appropriate conditions and the enzyme Taq polymerase, or equivalent enzyme, is used to synthesize copies of the DNA located between the primers. It is further envisioned that the particles of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding the desired product currently in use in the field. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element, is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired particle; the element does not encode the particle of this invention, but the DNA is present in the host cell genome. One next screens for cells making the particles of this invention, or increased or decreased levels of expression, as desired. The novel polypeptide is recovered and purified from recombinant cell cultures by known methods, including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, immunoaffinity chromatography, hydroxyapatite chromatography and lectin chromatography. Gene amplification and/or expression may be measured in a sample either directly, for example, by conventional Southern blotting or dot blot (DNA analysis) using an appropriately labelled probe, based on the sequences provided herein. Various labels may be employed, most commonly radionuclides, particularly 32 P. However, other techniques may also be employed, such as using biotin modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected. Gene expression, alternatively, may be measured either by Northern blotting to quantitate the transcription of mRNA (Thomas (1 980) Proc. Natl. Acad. Sci. USA 77:5201 -5205), dot blots, and in situ hybridization, or by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to directly quantitate the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product .coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu et at. (1980) Am. J. Clin. Path. 75:734-738. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal. Conveniently, the antibodies may be prepared against a synthetic peptide based on the DNA sequences provided herein. Such synthetic peptides may then be used as an immunogen in preparing antibodies by well-known techniques. Alternatively, the natural gene product and/or portions thereof may be isolated and used as the immunogen. In certain embodiments of this invention, cell lines with reduced expression of endogenous C-type retrovirus-like sequences are isolated by introduction of anti-sense or ribozyme genes, or by screening and selection procedures. While CHO cell lines are particularly appropriate for the application of these methods, these methods are used routinely with any host cell described above. Two approaches are illustrated for the isolation of a cell line with reduced or undetectable endogenous, C-type retrovirus gene expression. The first approach involves the introduction of anti-sense RNA genes or ribozyme genes into parental cell lines in order to specifically inhibit expression of endogenous C-type retrovirus genes. An alternate approach is the isolation of low-expressor subclones using screening and selection techniques. Both approaches are encompassed by this invention and are discussed in more detail below. The nucleic acid sequences of this invention permit the routine obtaining of cell lines with reduced C-type particle expression by enabling the introduction of specific antisense RNA or ribozyme genes. Inhibition of a specific gene product using antisense technology involves introduction of a gene into target cells which codes for an RNA transcript which is complementary (antisense) to messenger RNA of the gene product in question. Antisense RNA in the cell presumably base-pairs with the complementary mRNA and thereby inhibits translation or processing of message. The end result is a reduction in expression of a specific gene product. High-level expression of antisense RNA is achievable using current technology, as shown in Kasid eta/., Science 243: 1354-1356 [1 989]; Khoka eta/.. Science 243:947-950 [1 989]; Izant et a/., Science 229:345-352 [1 985]; von Ruden et al. , J. Virol. 63:677-682 [1989]; and Chang et a/., J. Virol. 61 :921 -924 [1987]). Optimization of levels of expression of antisense sequences is within the routine skill in the art, considering the expression levels of the "sense" sequence in the target cell and the potential adverse consequences of the production capabilities of the transformed cells which may result. For example, since nucleic acid blot analysis has revealed hundreds of copies of C-type related DNA sequences and moderately abundant C-type RNA transcripts in CHO cells, this approach may require high level expression of antisense RNA in order to be effective. Alternately, RNA may be introduced into the host cell which is complementary to the messenger RNA of the C-type retrovirus-like particle to prevent its translation. An alternative to the introduction of antisense RNA genes is the use of ribozymes. As described above, ribozymes are small RNA molecules that can cleave substrate RNAs in a sequence specific manner. Particularly preferred ribozymes for the practice of this invention are the "hammerhead" ribozymes described by Haseloff et al., Nature 334:585-591 [1 988]; this reference discloses the use of hammerhead ribozymes to cleave mRNAs at specific sites in vitro. With these hammerhead ribozymes, target sequences need only contain a GUA or GUC sequence at which cleavage occurs. Specificity of cleavage is determined by flanking sequences which hybridize to the ribozyme sequence. Thus, ribozymes can be engineered to cleave at any 18 bp RNA sequence flanking a GUA or GUC triplet, thus generating very precise specificity. Alternatively, RNA enzymes with highly specific endoribonuclease activities may be utilized in the practice of this invention, such as those disclosed by Koizumi et a/., FEBS Lett. 239:285-288 [1 988]. Utilizing the sequences of this invention, antisense or ribozyme genes specific for several regions of coding C-type mRNA are constructed and introduced into host cells using standard transfection protocols. Parental cell lines suitable for construction of recombinant clones are isolated using unique selectable markers so as not to interfere with the utility of these cells for subsequent genetic manipulation. It may be desirable to use amplification methods to facilitate isolation of clones and allow for amplification of antisense or ribozyme genes if desired. Cell lines are then evaluated for expression of endogenous C-type products. Detection of expression may be made by immunoassay for structural proteins, enzymatic assay for reverse traπscriptase activity, blot analysis for RNA transcripts, and electron microscope examination of cell sections for the presence of C-type particles. In other embodiments, low expressor subclones are isolated through routine screening as described above. For example, subclones of parental cells are evaluated for expression of C-type RNA sequences by blot analysis using probes consisting of fragments of the sequences claimed herein. Low expressing subclones are subjected to additional rounds of screening until RNA levels are undetectable or not reduced further. Different transfected cell lines may vary significantly in their level of C-type mRNA expression and it is anticipated that variation will occur in non-transfected subclones as well. This invention also contemplates more powerful selection schemes. Genes encoding envelope proteins for C-type particles are isolated from cDNA or genomic libraries using the cDNA provided herein as probe. An expression vector is then directly linked to envelope coding sequences at the DNA level and so as to partially overlap at the mRNA level. Following provision of sequence from a substantial open reading frame, a protein construct is made and expressed in a suitable recombinant host such as £ coli according to known techniques. Next, anti-envelope protein antibodies are then generated by immunization with the protein. Since retrovirus envelope proteins are expressed on the surface of cells secreting C-type particles, many direct selection schemes employing C-type envelope antibodies can be employed. One embodiment involves incubation of a host cell in the presence of anti-envelope protein antibodies and complement. The antibody and complement lyse expressor cell lines and leave only non-expressor cells as survivors. Some routine experimentation with antibody concentrations may be necessary in order to select for low-expressor cells in the event that non-expressor cells do not exist in the initial population. A second approach using the fluorescence activated cell sorter (FACS) allows flexibility in the selection of low-expressor cells. Host cells are stained using anti-envelope primary antibody and a fluorescein conjugated second antibody. High expressor cells show high fluorescence and low expressors low fluorescence. Physical sorting of individual cells by FACS according to fluorescence intensity is used to enrich for a population of cells which express low-levels of C-type envelope protein. Multiple rounds of FACS sorting enhances the selection procedure. Once a population of low-expressing cells is obtained, subclones are propagated and analyzed more rigorously for C-type expression as outlined for the screening protocol above. The nucleic acid sequences encoding the retrovirus-like particles of this invention are desirably incorporated into a host cell in more than one copy. It is understood that the application of the teachings of the present invention to a specific problem or situation will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation, use, and manufacture appear below, but should not be construed to limit the invention. Example: Preparation and analysis of C-type particles MATERIALS AND METHODS Cells. Extracellular particles were prepared from culture fluid of the recombinant CHO cell subclone, 3-3000-44 {Lasky, L.A. et a/., Science 233:209-212 [1 986]}. This subclone was derived from dihydrofolate reductase (dhfr) deficient CHO-DUXB1 1 cells {Lubiniecki, A. S. et al., Develop. Biol. Standard. 70:187-191 [1989]; Heine, U. I. et al., J. Gen. Virol. 44:45-55 [1979]} following transfection with an expression vector containing the genes for murine dhfr and recombinant envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1 ). The CHO-K1 cell line (progenitor of the CH0-DUXB1 1 line) was originally derived from an ovarian biopsy of an adult Chinese hamster (Cricetulus griseus) {Lieber, M. M. et al., Science 182:56-58 [1973]} and was obtained from the American Type Culture Collection (ATCC CCL 61 ). The mouse myeloma cell line, X63-Ag8.653 {Lubiniecki, A. S. and L. H. May, Develop. Biol. Standard. 60: 141 -146 [1 985]}, and the human diploid fibroblast cell line, MRC5 {Hojman, F. et al., Develop. Biol. Standard. 70:195-202 [1989] (ATCC CCL 171 )}, were also obtained from ATCC. Centrifugal concentrates of cell culture fluid. Cell culture fluid used for the preparation of particles was obtained, from cells grown under serum-free manufacturing conditions. Typically 20-30 liters of clarified cell culture fluid was passed through a high-capacity, continuous-flow ultracentrifuge rotor (Beckman model CF32) at 100,000 x g. Pelleted particles were harvested by scraping from the walls of the rotor in 1 50 M NaCI, 10 mM Tris (pH 7.5) containing 0.1 % BSA (TN-BSA). The harvested particles were then pelleted in a Beckman Ti45 rotor at 100,000 x g for 90 minutes, resuspended in a final volume of 4-5 mis of TN-BSA, and stored at -80 °C. This procedure results in a 4000-6000 fold concentration of particles present in starting cell culture fluid. Reverse transcriptase (RT) assays. Reverse transcriptase assays were performed in a total volume of 0.1 mis using 0.05 mis of sample per assay. Samples were treated with 0.2% triton-X100 for 30 minutes on ice to solubilize RT activity prior to a 1 hour assay incubation at 37°C. Incorporation of [ 3 H]-TTP into DNA using a poly(rA):oligo(dT) template in the presence of 0.2 mM manganese was monitored by counting radioactivity bound to DE81 filters. Polymerase activity in the presence of poly(dA):oligo(dT) template was monitored as a control for the presence of non-specific polymerase activity. RT activity in the presence of manganese or 5 mM magnesium was compared for some samples. A modified assay using 15 μ\ of sample in a total volume of 65 μ\, and [ 32 P]-TTP as label was used in some experiments. Sucrose gradient fractionation. For purification of particles, a double sucrose density gradient procedure was used. Concentrated culture fluid was adjusted to 50% (w/w) sucrose by addition of solid sucrose, and overlayed with equal volumes of 40%, 30%, and 20% sucrose in TN buffer (10 mM Tris-HCI pH 7.5, 150 mM NaCI). After centrifuging overnight at 25K rpm in an SW27 rotor, RT containing peak fractions were pooled, dialyzed vs. TN buffer, and layered on top of a linear, preformed 10-60% (w/w) continuous sucrose gradient in TN buffer. Centrifugation for 2 hours at 39K rpm in an SW41 rotor was sufficient to band particles at their appropriate density. Electron microscope analysis of sucrose gradient fractions. Samples of sucrose gradient fractions (10-50 μ\) were dialyzed vs. TN buffer and spotted onto grids. Particles were allowed to settle for at least 30 min., after which they were negatively stained using uranyl acetate and visualized in a transmission electron microscope. Detection of C-type immunoreactive capsid core polypeptides using protein blot analyses. Protein samples were fractionated on reducing SDS-polyacrylamide gels and transferred electrophoretically to Immobilon filters (Pharmacia). Primary antisera (goat anti-feline leukemia virus p27 sera) was used at a 1 :400 dilution. A secondary detector antibody (donkey anti-goat IgG coupled to horseradish peroxidase) was used at a dilution of 1 :1000. The signal was developed using 4-chloro, 1 -naphthol/hydrogen peroxide as substrate. Characterization of nucleic acids present in retrovirus-like particles. Nucleic acids were extracted from sucrose gradient fractions by phenol-chloroform extraction. Samples were applied to membranes (Genescreen plus; NEN Research Products) using a slot-blot manifold (Schleicher and Schuell mini-fold). Hybridizations were performed at 42°C in buffer containing 0.5 M NaCI, 0.1 M HEPES (pH 7.2), 5mM EDTA, 0.1 % sodium pyrophosphate, 5X Denhardt's solution, 100 gs/ml denatured salmon sperm DNA and either 50% formamide (high stringency) or 25% formamide (low stringency). Cloned probe for the endogenous, polytropic murine leukemia virus (MLV) isolate, MX27 {Stoye, J.P. , J. Virol. 61 :2659-2669 [1987]} was provided by J. M. Coffin and J. P. Stoye. Probes for endogenous CHO intracisternal A-particle sequences (pCHIAP.SW2 for family I and pCHIAP.YL9 for family II) have been described elsewhere {Anderson, 1990, supra). Probe for murine yff-actin was synthesized based on published sequence {Tokunaga, K., Nucleic Acids Res. 14:28-29 [1986]} and consisted of 45mer oligodeoxynucleotides of opposite polarity which contained complementary sequences at their 3' ends. All probes were radioactively labeled by incorporation of σ-[ 32 P]-dCTP using nick translation for plasmid probes or Klenow fragment extension for overlapping oligodeoxynucleotide probes. Isolation and characterization of C-type cDNA clones. C-type related sequences were isolated from a randomly primed cDNA library of particle RNA in Λgt10. Low stringency hybridization using the MLV-MX27 probe was used to identify plaques of interest. DNA sequencing was performed using the dideoxy chain termination method on subcloned single-stranded template {Saπger, F., Proc. Nat/. Acad. Sci. USA 74:3463-3467 [1977]}. Genomic DNA blots of Chinese hamster DNA. Standard procedures were used for preparation of genomic DNA from CHO cells {Maniatis, T. et al. , 1 982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.}. High molecular weight Chinese hamster liver DNA was kindly supplied by K. K. Lueders. DNA was digested to completion using the restriction enzyme Hindlll, and 2 μg samples were fractionated by electrophoresis on 0.7% agarose gels. After capillary transfer of DNA to charged nylon membranes (Genescreen plus, NEN Research Products), hybridizations were performed using conditions and probes described above for slot blots. RESULTS Purification of RT-containing particles from culture fluid of CHO cells. A protocol was devised for purification of extracellular, retrovirus-like particles from CHO cells which involved centrifugal concentration of large volumes of culture fluid, followed by fractionation on 2 sequential sucrose density gradients (see Methods and Materials). Cell culture fluid which had been concentrated 4000-fold by ultracentrifugation was initially fractionated by centrifugation to equilibrium in a sucrose step gradient. Peak reverse transcriptase (RT)-containing fractions at the appropriate density (1 .12-1 .14 g/ml) were pooled, dialyzed, and layered on top of a continuous 10-60% preformed sucrose gradient and again centrifuged to equilibrium. RT profiles of the first and second gradients in a typical purification protocol are shown in Fig. 1 . A single peak of RT activity with only background activity in flanking fractions was observed on the second sucrose gradient. Fractions comprising the RT peak of the second gradient were pooled for subsequent characterization. RT activity of purified Rauscher murine leukemia virus banded at a similar density in identical gradients (not shown). Preferential polymerase activity in the presence of poly(rA) template compared to poly(dA) template confirmed that the polymerase activity of peak fractions represented reverse transcriptase, and preferential activity in the presence of manganese compared to magnesium suggested that the particles were related to mammalian C-type retroviruses (not shown). Electron microscope (EM) evaluation of purified particles from CHO 3-3000-44 cells. Samples of peak RT-containing fractions were examined in the electron microscope for the presence of retrovirus-like particles. After negative staining with uranyl acetate, pleiomorphic particles comparable in size and morphology to retroviruses visualized by others using this methodology were observed (Fig. 2). Protein and nucleic acid content of purified retrovirus-like particles. Pools of 4 fractions each from the second sucrose gradient of a particle purification (shown in Fig. 1 B) were combined and tested for the presence of retrovirus structural antigens and nucleic acid sequences. Western blot analysis of gradient pools using antisera to purified p27 core protein of feline leukemia virus (FeLV, a mammalian C-type retrovirus) revealed the presence of a 31 kd core protein (p31 ), as well as a 64 kd gag precursor (p64) in the gradient pool containing fractions with peak RT activity (Fig. 3A). Nucleic acids were isolated from each pool, applied to membranes using a slot-blot manifold, and hybridized with retrovirus and control probes (Fig. 3B). Nucleic acids specifically hybridizing to the murine leukemia virus (C-type) probe (MLV-MX27, see Materials and Methods) were observed only in the pool comprised of fractions with RT activity and containing detectable p31 and p64 polypeptides. Nucleic acids from RT and p31 containing fractions also hybridized to pooled probe for family I and family II CHO cell intracisternal A-particle (IAP) sequences (pCHIAP.SW2 and pCHIAP.YL9, see Materials and Methods). Subsequent experiments revealed homology to family II (pCHIAP.YL9), but not to family I (pCHIAP.SW2) IAP sequences (not shown). Nucleic acids with homology to a major cellular mRNA (S-actin) were not detected in any gradient fractions. Hybridization signals for retrovirus probes (MLV-MX27 and CHIAP-YL9) were reduced significantly when nucleic acids were treated with RNAse or alkali prior to blotting, but no reduction in signal intensity was observed when samples were treated with RNAse free DNAse prior to blotting. These findings indicate that the nucleic acids detected were RNA and not DNA. The presence of RNA in particles is consistent with the morphological and immunological characterization of these particles as retrovirus related. Characterization of particle cDNA sequences homologous to MLV. Several cDNA clones of purified particle RNA which hybridized to MLV probe were isolated and characterized. Three of the clones were characterized in detail. All showed homology to the endonuclease domain of MLV. The largest clone (pCHOC.MLI O, 949 bp) exhibited 73% nucleotide identity with the published sequence of Moloney MLV {Shinnick, T. supra Nature 1981 } (Fig. 4, Table 1 ). Reduced homology was found to endonuclease domains of C-type retroviruses of evolutionarily divergent species suggesting that the pCHOC.MLI O clone is most closely related to rodent C-type retroviruses (Table 1 ). The pCHOC.MLI O sequence contained multiple interruptions of potential coding sequences in all 3 reading frames and therefore was not capable of encoding an intact endonuclease (Fig. 5). Table 1. Nucleotide homology of pCHOC.MLI OcDNA to mammalian C-type retrovirus genomes. % nucleotide homology C-type retrovirus identity score' Moloney murine leukemia virus 74 2008 (Shinnick et al . , 1981 ) {supra} Feline leukemia virus 70 1910 (Donahue et al . , 1988 ) {J.Virol . 62 : 722-73176} Baboon endogenous virus 64 1714 (Kato et al . , 1987 ) {Jpn. J. Genetics 62 : 127-137 } * * * * * Presence of homologous DNA sequences in the Chinese hamster genome. Southern blot analysis of Chinese hamster DNA using the pCHOC.MLI O clone as probe revealed that conserved, homologous sequences were present at 100 to 300 copies per genome in DNA of parental and recombinant CHO cell lines, as well as in DNA isolated from a Chinese hamster liver (Fig. 6A). Homologous sequences were not detected in DNA isolated from human MRC5 cells or mouse myeloma cells using the same high stringency hybridization conditions (data not shown). CHO IAP family II RNA sequences were also detected in gradient purified particles (see above). Related DNA sequences have previously been demonstrated to exist as a moderately repetitive family in the genomes of recombinant and parental CHO cell lines {Anderson et al. , supra 1990}. Comparison of DNA from several CHO cell lines with DNA from Chinese hamster liver by Southern blot analysis using CHO IAP family II probe (Fig. 6B) revealed that this conserved family of repetitive sequences is also present in the Chinese hamster germline. DISCUSSION Particles morphologically similar to retroviruses have previously been observed in CHO cells, but detailed characterization has not been reported. The use of high-capacity, flow-through ultracentrifugation to concentrate extracellular, retrovirus-like particles from large quantities of culture fluid of a recombinant CHO cell line has facilitated purification and biochemical characterization of these particles. Extracellular particles of CHO cells are similar to those of characterized mammalian C-type retroviruses by a number of criteria. They band in a sucrose gradient at an appropriate density, and exhibit RT activity with a preference for manganese. Polypeptides of the particles are immunologically related to those of mammalian C-type retroviruses, and RNA ' Based on algorithm parameters described by Fitch and Smith (1983) {81}. from purified particles specifically hybridizes to a cloned murine C-type genome under low stringency conditions. Purified particles also contained RNA which specifically hybridized to a cloned probe representing one of two characterized families of CHO cell intracisternal A-particle (CHIAP) related sequences {Anderson et al., supra 1990}. One possible explanation for this result is that 2 types of particles with similar buoyant densities in sucrose gradients are present in supernatants of CHO cells. At least one of these particles must contain structural antigens which cross-react with C-type antisera. Alternatively, a single type of particle containing C-type structural proteins may be present which encapsidates the two different RNAs. Examples of retrovirus particles packaging heterologous retrovirus RNA species have previously been described {Scolnick, E., J. Virol. 29:964-972 [1990]; Sherwin, S.A, J. Virol. 26:257-264 [1978]}. Another possibility which should be considered is that the particle RNA represents the product of a recombinant provirus gene composed of sequences from both unrelated retrovirus classes. The available data do not allow differentiation between these alternatives. Sequence analysis of a cDNA clone representing purified particle RNA revealed significant nucleotide homology with endonuclease encoding genes of several mammalian C-type retroviruses (Table 1 ). However, the cloned cDNA sequence contained no open reading frames capable of encoding an intact endonuclease. Since a functional retrovirus endonuclease is required for provirus integration, an obligatory step in the retrovirus replication cycle, these findings provide one possible explanation for the non-infectious nature of the particles observed in CHO cells. Nucleotide homology of particle cDNA to murine C-type virus genomes was greater than that observed to C-type retrovirus genomes of evolutionarily more distant mammalian species suggesting that the particles are of rodent origin. Furthermore, comparison of DNA from several CHO cell lines and Chinese hamster liver using Southern blot analysis revealed that both types of retrovirus-like sequences identified in purified extracellular particles (CHO IAP family II and C-type) are present in the germline of Chinese hamsters. It is therefore likely that the extracellular retrovirus-like particles of CHO cells are the products of endogenous provirus elements present in the germline of Chinese hamsters. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: GENENTECH, INC. (ii) TITLE OF INVENTION: Chinese Hamster Ovary Cell Retrovirus-like Particles (iϋ) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: pa in (Genentech) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 07-NOV-1991 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 07/611,529 (B) FILING DATE: 09-NOV-1990 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Adler, Carolyn R. (B) REGISTRATION NUMBER: 32,324 (C) REFERENCE/DOCKET NUMBER: 678 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/266-2614 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 949 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GAATTCAATG TCCTTGTGGG GAAGAACGAT ATTCTAAAAC AGGTAACTGA 50 GCAATGTGAT GCGTGCGCCC GAGTCAACGC ATCCAGACTG AAGCTTCCTC 100 CCGGGAACCG GTCAGAGGCT ACCGGCCCGG AACACATTGG GAGATAGATT 150 TCACTGAGAT TAAACCAGGA AAATATGGAT ACAAGTATCT ATTAATTTTT 200 GTAGACACCT TTTCAGGATG GGTTGAAGCC TTCCCTACTA AACATGAAAC 250 AGCCAGATCG TTACTAAGAA ATTGCTTGAA GAAATCTTTC CCCGTTATCG 300 GATGCCTCAG GTATTGGGAA CAGACAATGG GCCCGCCTTC GTCTCCAGGT 350 AAGTCAGTCA GTGGCCACCT TATTGGGGAT TGATTGGAAA TTACATTGTG 400 CTTATAGACC CCAAAGTTCA GGACAGGTAG AAAGGATGAA TAGAACAATC 450 AAGGAGACTT TAACAAAATT GTCGCTTGCA ACTGGCACTA GAGAGCTGGG 500 TCCTCCTACT CCCCCTAGCA CTCTACCGCG CTCGTAATAC CCCTGGACCA 550 CATGGGCTCA CACCCTTTGA GATCCTGTAT GGAGTACCTA GCTCCTATCA 600 TTAACTTTCT TGATCAAGAT GTCTCAGTTT TGCTAACTCC CCTTCTCTCC 650 AAGCTCATTT ACAGGCCCTC CAACTAGTAC AACGGGAGGT CTGGAAACCC 700 CTTGCTCAAG CTTATAAAGA CCAGAGGGAC CATCCCACCA TCCCCCATTC 750 CTACCAGATC GGGGACACTG TTTGGGTCCG GCGTCACCAG GCCAAGAACC 800 TTGAACCCCG CTGGAAGGG CCCTACATCG TTTTGCTTAC CACTCCCACC 850 GCACTCAAGG TAGACGGCAT TGCAGCTTGG ATACATGCTT CACATGTAAA 900 GCCAGCCCAA CCCACCGATT CAGCCACTGC ATCAGAATGG AGCCACACC 949 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 949 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GGTGTGGCTC CATTCTGATG CAGTGGCTGA ATCGGTGGGT TGGGCTGGCT 50 TTACATGTGA AGCATGTATC CAAGCTGCAA TGCCGTCTAC CTTGAGTGCG 100 GTGGGAGTGG TAAGCAAAAC GATGTAGGGT CCCTTCCAGC GGGGTTCAAG 150 GTTCTTGGCC TGGTGACGCC GGACCCAAAC AGTGTCCCCG ATCTGGTAGG 200 AATGGGGGAT GGTGGGATGG TCCCTCTGGT CTTTATAAGC TTGAGCAAGG 250 GGTTTCCAGA CCTCCCGTTG TACTAGTTGG AGGGCCTGTA AATGAGCTTG 300 GAGAGAAGGG GAGTTAGCAA AACTGAGACA TCTTGATCAA GAAAGTTAAT 350 GATAGGAGCT AGGTACTCCA TACAGGATCT CAAAGGGTGT GAGCCCATGT 400 GGTCCAGGGG TATTACGAGC GCGGTAGAGT GCTAGGGGGA GTAGGAGGAC 450 CCAGCTCTCT AGTGCCAGTT GCAAGCGACA ATTTTGTTAA AGTCTCCTTG 500 ATTGTTCTAT TCATCCTTTC TACCTGTCCT GAACTTTGGG GTCTATAAGC 550 ACAATGTAAT TTCCAATCAA TCCCCAATAA GGTGGCCACT GACTGACTTA 600 CCTGGAGACG AAGGCGGGCC CATTGTCTGT TCCCAATACC TGAGGCATCC 650 GATAACGGGG AAAGATTTCT TCAAGCAATT TCTTAGTAAC GATCTGGCTG 700 TTTCATGTTT AGTAGGGAAG GCTTCAACCC ATCCTGAAAA GGTGTCTACA 750 AAAATTAATA GATACTTGTA TCCATATTTT CCTGGTTTAA TCTCAGTGAA 800 ATCTATCTCC CAATGTGTTC CGGGCCGGTA GCCTCTGACC GGTTCCCGGG 850 AGGAAGCTTC AGTCTGGATG CGTTGACTCG GGCGCACGCA TCACATTGCT 900 CAGTTACCTG TTTTAGAATA TCGTTCTTCC CCACAAGGAC ATTGAATTC 949

Claims: CLAIMS 1 . A nucleic acid sequence comprising a sequence that hybridizes under stringent conditions to the following DNA sequence (Seq. ID No. 1 ): GAATTCAATG TCCTTGTGGG GAAGAACGAT ATTCTAAAAC AGGTAACTGA 50 GCAATGTGAT GCGTGCGCCC GAGTCAACGC ATCCAGACTG AAGCTTCCTC 100 CCGGGAACCG GTCAGAGGCT ACCGGCCCGG AACACATTGG GAGATAGATT 150 TCACTGAGAT TAAACCAGGA AAATATGGAT ACAAGTATCT ATTAATTTTT 200 GTAGACACCT TTTCAGGATG GGTTGAAGCC TTCCCTACTA AACATGAAAC 250 AGCCAGATCG TTACTAAGAA ATTGCTTGAA GAAATCTTTC CCCGTTATCG 300 GATGCCTCAG GTATTGGGAA CAGACAATGG GCCCGCCTTC GTCTCCAGGT 350 AAGTCAGTCA GTGGCCACCT TATTGGGGAT TGATTGGAAA TTACATTGTG 400 CTTATAGACC CCAAAGTTCA GGACAGGTAG AAAGGATGAA TAGAACAATC 450 AAGGAGACTT TAACAAAATT GTCGCTTGCA ACTGGCACTA GAGAGCTGGG 500 TCCTCCTACT CCCCCTAGCA CTCTACCGCG CTCGTAATAC CCCTGGACCA 550 CATGGGCTCA CACCCTTTGA GATCCTGTAT GGAGTACCTA GCTCCTATCA 600 TTAACTTTCT TGATCAAGAT GTCTCAGTTT TGCTAACTCC CCTTCTCTCC 650 AAGCTCATTT ACAGGCCCTC CAACTAGTAC AACGGGAGGT CTGGAAACCC 700 CTTGCTCAAG CTTATAAAGA CCAGAGGGAC CATCCCACCA TCCCCCATTC 750 CTACCAGATC GGGGACACTG TTTGGGTCCG GCGTCACCAG GCCAAGAACC 800 TTGAACCCCG CTGGAAGGGA CCCTACATCG TTTTGCTTAC CACTCCCACC 850 GCACTCAAGG TAGACGGCAT TGCAGCTTGG ATACATGCTT CACATGTAAA 900 GCCAGCCCAA CCCACCGATT CAGCCACTGC ATCAGAATGG AGCCACACC 949 2. The nucleic acid of claim 1 that contains at least about ten nucleotides. 3. An isolated nucleic acid sequence having the following sequence (Seq. ID No. 1 ): GAATTCAATG TCCTTGTGGG GAAGAACGAT ATTCTAAAAC AGGTAACTGA 50 GCAATGTGAT GCGTGCGCCC GAGTCAACGC ATCCAGACTG AAGCTTCCTC 100 CCGGGAACCG GTCAGAGGCT ACCGGCCCGG AACACATTGG GAGATAGATT 150 TCACTGAGAT TAAACCAGGA AAATATGGAT ACAAGTATCT ATTAATTTTT 200 GTAGACACCT TTTCAGGATG GGTTGAAGCC TTCCCTACTA AACATGAAAC 250 AGCCAGATCG TTACTAAGAA ATTGCTTGAA GAAATCTTTC CCCGTTATCG 300 GATGCCTCAG GTATTGGGAA CAGACAATGG GCCCGCCTTC GTCTCCAGGT 350 AAGTCAGTCA GTGGCCACCT TATTGGGGAT TGATTGGAAA TTACATTGTG 400 CTTATAGACC CCAAAGTTCA GGACAGGTAG AAAGGATGAA TAGAACAATC 450 AAGGAGACTT TAACAAAATT GTCGCTTGCA ACTGGCACTA GAGAGCTGGG 500 TCCTCCTACT CCCCCTAGCA CTCTACCGCG CTCGTAATAC CCCTGGACCA 550 CATGGGCTCA CACCCTTTGA GATCCTGTAT GGAGTACCTA GCTCCTATCA 600 TTAACTTTCT TGATCAAGAT GTCTCAGTTT TGCTAACTCC CCTTCTCTCC 650 AAGCTCATTT ACAGGCCCTC CAACTAGTAC AACGGGAGGT CTGGAAACCC 700 CTTGCTCAAG CTTATAAAGA CCAGAGGGAC CATCCCACCA TCCCCCATTC 750 CTACCAGATC GGGGACACTG TTTGGGTCCG GCGTCACCAG GCCAAGAACC 800 TTGAACCCCG CTGGAAGGGA CCCTACATCG TTTTGCTTAC CACTCCCACC 850 GCACTCAAGG TAGACGGCAT TGCAGCTTGG ATACATGCTT CACATGTAAA 900 GCCAGCCCAA CCCACCGATT CAGCCACTGC ATCAGAATGG AGCCACACC 949 or a fragment thereof which retains hybridization specificity. 4. The fragment of claim 3 having at least about ten nucleotides. 5. An isolated nucleic acid sequence having the following sequence (Seq. ID No. GGTGTGGCTC CATTCTGATG CAGTGGCTGA ATCGGTGGGT TGGGCTGGCT 50 TTACATGTGA AGCATGTATC CAAGCTGCAA TGCCGTCTAC CTTGAGTGCG 100 GTGGGAGTGG TAAGCAAAAC GATGTAGGGT CCCTTCCAGC GGGGTTCAAG 150 GTTCTTGGCC TGGTGACGCC GGACCCAAAC AGTGTCCCCG ATCTGGTAGG 200 AATGGGGGAT GGTGGGATGG TCCCTCTGGT CTTTATAAGC TTGAGCAAGG 250 GGTTTCCAGA CCTCCCGTTG TACTAGTTGG AGGGCCTGTA AATGAGCTTG 300 GAGAGAAGGG GAGTTAGCAA AACTGAGACA TCTTGATCAA GAAAGTTAAT 350 GATAGGAGCT AGGTACTCCA TACAGGATCT CAAAGGGTGT GAGCCCATGT 400 GGTCCAGGGG TATTACGAGC GCGGTAGAGT GCTAGGGGGA GTAGGAGGAC 450 CCAGCTCTCT AGTGCCAGTT GCAAGCGACA ATTTTGTTAA AGTCTCCTTG 500 ATTGTTCTAT TCATCCTTTC TACCTGTCCT GAACTTTGGG GTCTATAAGC 550 ACAATGTAAT TTCCAATCAA TCCCCAATAA GGTGGCCACT GACTGACTTA 600 CCTGGAGACG AAGGCGGGCC CATTGTCTGT TCCCAATACC TGAGGCATCC 650 GATAACGGGG AAAGATTTCT TCAAGCAATT TCTTAGTAAC GATCTGGCTG 700 TTTCATGTTT AGTAGGGAAG GCTTCAACCC ATCCTGAAAA GGTGTCTACA 750 AAAATTAATA GATACTTGTA TCCATATTTT CCTGGTTTAA TCTCAGTGAA 800 ATCTATCTCC CAATGTGTTC CGGGCCGGTA GCCTCTGACC GGTTCCCGGG 850 AGGAAGCTTC AGTCTGGATG CGTTGACTCG GGCGCACGCA TCACATTGCT 900 CAGTTACCTG TTTTAGAATA TCGTTCTTCC CCACAAGGAC ATTGAATTC 949 or a fragment thereof which retains hybridization specificity. 6. The fragment of claim 5 having at least about ten nucleotides. 7. A nucleic acid sequence comprising a sequence that hybridizes under stringent conditions to the following DNA sequence (Seq. ID No. 2): GGTGTGGCTC CATTCTGATG CAGTGGCTGA ATCGGTGGGT TGGGCTGGCT 50 TTACATGTGA AGCATGTATC CAAGCTGCAA TGCCGTCTAC CTTGAGTGCG 100 GTGGGAGTGG TAAGCAAAAC GATGTAGGGT CCCTTCCAGC GGGGTTCAAG 150 GTTCTTGGCC TGGTGACGCC GGACCCAAAC AGTGTCCCCG ATCTGGTAGG 200 AATGGGGGAT GGTGGGATGG TCCCTCTGGT CTTTATAAGC TTGAGCAAGG 250 GGTTTCCAGA CCTCCCGTTG TACTAGTTGG AGGGCCTGTA AATGAGCTTG 300 GAGAGAAGGG GAGTTAGCAA AACTGAGACA TCTTGATCAA GAAAGTTAAT 350 GATAGGAGCT AGGTACTCCA TACAGGATCT CAAAGGGTGT GAGCCCATGT 400 GGTCCAGGGG TATTACGAGC GCGGTAGAGT GCTAGGGGGA GTAGGAGGAC 450 CCAGCTCTCT AGTGCCAGTT GCAAGCGACA ATTTTGTTAA AGTCTCCTTG 500 ATTGTTCTAT TCATCCTTTC TACCTGTCCT GAACTTTGGG GTCTATAAGC 550 ACAATGTAAT TTCCAATCAA TCCCCAATAA GGTGGCCACT GACTGACTTA 600 CCTGGAGACG AAGGCGGGCC CATTGTCTGT TCCCAATACC TGAGGCATCC 650 GATAACGGGG AAAGATTTCT TCAAGCAATT TCTTAGTAAC GATCTGGCTG 700 TTTCATGTTT AGTAGGGAAG GCTTCAACCC ATCCTGAAAA GGTGTCTACA 750 AAAATTAATA GATACTTGTA TCCATATTTT CCTGGTTTAA TCTCAGTGAA 800 ATCTATCTCC CAATGTGTTC CGGGCCGGTA GCCTCTGACC GGTTCCCGGG 850 AGGAAGCTTC AGTCTGGATG CGTTGACTCG GGCGCACGCA TCACATTGCT 900 CAGTTACCTG TTTTAGAATA TCGTTCTTCC CCACAAGGAC ATTGAATTC 949 8. The nucleic acid of claim 7 that contains at least about ten nucleotides. 9. The nucleic acid of claim 3 further comprising a promoter operably linked to said nucleic acid sequence. 10. The nucleic acid sequence of claim 3 further comprising an origin of replication operative in a unicellular organism. 1 . . The sequence of claim 1 that is a genomic sequence. 12. An expression vector comprising the nucleic acid sequence of claim 1 operably linked to control sequences recognized by a host transformed by the vector. 13. The vector of claim 12 that is a plasmid. 14. A host cell transformed with the vector of claim 12. 15. The host cell of claim 14 which is a mammalian cell. 16. A host cell containing the nucleic acid of claim 1 operably linked to exogenous control sequences recognized by the host cell. 17. The host cell of claim 16 wherein said nucleic acid sequence is present in more than one copy. 18. The host cell of claim 16 which is a mammalian cell. 19. An isolated mammalian cell having decreased or increased expression of endogenous C-type retrovirus sequences. 20. A method for obtaining cells having increased or decreased transcription of the nucleic acid of claim 1 comprising: a. providing cells containing said nucleic acid; b. introducing into the cells a transcription modulating element; and c. screening the cells for a cell in which the transcription of said nucleic acid is increased or decreased. 21 . A method for obtaining cells having decreased expression of endogenous C-type retrovirus sequences comprising the following steps: a. obtaining a cell having detectable levels of an endogenous C-type retrovirus sequence; b. introducing into said cell nucleic acid which codes for an RNA transcript which is complementary to messenger RNA of the nucleic acid of the endogenous C- type retrovirus sequence. 22 The method of claim 21 , wherein said C-type retrovirus sequence is the sequence of claim 3. 23. The method of claim 21 , wherein said complementary nucleic acid is the sequence of claim 5. 24. A method for obtaining cells having decreased expression of endogenous C-type retrovirus sequences comprising the following steps: a. obtaining a cell having detectable levels of an endogenous C-type retrovirus sequence; b. introducing into said cell RNA which is complementary to messenger RNA of the nucleic acid of the endogenous C-type retrovirus sequence. 25. The method of claim 24, wherein said C-type retrovirus sequence is the sequence of claim 3. 26. The method of claim 24, wherein said complementary nucleic acid is the sequence of claim 5. 27. A method for obtaining cells having decreased expression of endogenous C-type retrovirus sequences comprising the following steps: a. obtaining a cell having a detectable C-type retrovirus RNA sequence; b. introducing into said cell a ribozyme nucleic acid sequence which cleaves RNA flanking the C-type retrovirus RNA sequence. 28. The method of claim 27, wherein said C-type retrovirus sequence is the sequence of claim 3. 29. A method comprising culturing a cell containing the nucleic acid of claim 3 wherein a transcription modulatory element is inserted into the DNA flanking said nucleic acid in proximity and orientation sufficient to influence the transcription of the nucleic acid. 30. A method for detecting retroviral-like nucleic acid sequences in a test sample which comprises determining hybridization between the test sample and a probe specific for the sequence of claim 3. 31 . A method for detecting retroviral-like nucleic acid sequences in a test sample which comprises determining hybridization between the test sample and a probe specific for the sequence of claim 5. 32. A method for determining the presence of retroviral-like nucleic acid expression products in a test sample comprising the use of polymerase chain reaction. 33. A method for determining the presence of retroviral-like nucleic acid expression products in a test sample comprising the use of an immunoassay directed against such expression products. 34. At least one retrovirus-like particle encoded by the following sequence (Seq. ID No. 1 ): GAATTCAATG TCCTTGTGGG GAAGAACGAT ATTCTAAAAC AGGTAACTGA 50 GCAATGTGAT GCGTGCGCCC GAGTCAACGC ATCCAGACTG AAGCTTCCTC 100 CCGGGAACCG GTCAGAGGCT ACCGGCCCGG AACACATTGG GAGATAGATT 150 TCACTGAGAT TAAACCAGGA AAATATGGAT ACAAGTATCT ATTAATTTTT 200 GTAGACACCT TTTCAGGATG GGTTGAAGCC TTCCCTACTA AACATGAAAC 250 AGCCAGATCG TTACTAAGAA ATTGCTTGAA GAAATCTTTC CCCGTTATCG 300 GATGCCTCAG GTATTGGGAA CAGACAATGG GCCCGCCTTC GTCTCCAGGT 350 AAGTCAGTCA GTGGCCACCT TATTGGGGAT TGATTGGAAA TTACATTGTG 400 CTTATAGACC CCAAAGTTCA GGACAGGTAG AAAGGATGAA TAGAACAATC 450 AAGGAGACTT TAACAAAATT GTCGCTTGCA ACTGGCACTA GAGAGCTGGG 500 TCCTCCTACT CCCCCTAGCA CTCTACCGCG CTCGTAATAC CCCTGGACCA 550 CATGGGCTCA CACCCTTTGA GATCCTGTAT GGAGTACCTA GCTCCTATCA 600 TTAACTTTCT TGATCAAGAT GTCTCAGTTT TGCTAACTCC CCTTCTCTCC 650 AAGCTCATTT ACAGGCCCTC CAACTAGTAC AACGGGAGGT CTGGAAACCC 700 CTTGCTCAAG CTTATAAAGA CCAGAGGGAC CATCCCACCA TCCCCCATTC 750 CTACCAGATC GGGGACACTG TTTGGGTCCG GCGTCACCAG GCCAAGAACC 800 TTGAACCCCG CTGGAAGGGA CCCTACATCG TTTTGCTTAC CACTCCCACC 850 GCACTCAAGG TAGACGGCAT TGCAGCTTGG ATACATGCTT CACATGTAAA 900 GCCAGCCCAA CCCACCGATT CAGCCACTGC ATCAGAATGG AGCCACACC 949

Inventors: ANDERSON KEVIN P, ANDERSON, KEVIN, P.
Applicants: GENENTECH INC, GENENTECH, INC.
Application year: 1991
Main classification: C12N5
IPC codes: A61K38, C07K14, C12N5, C12N7, C12N15